PE
TAK icon

PCM Encore’s Takeda Pharmaceutical TAK Stock Holding History

PCM Encore’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.22M Sell
76,278
-627
-0.8% -$10.4K 0.21% 87
2026
Q1 		$1.42M Buy
76,905
+1,115
+1% +$19.6K 0.29% 71
2025
Q4 		$1.18M Buy
+75,790
New +$1.08M 0.25% 79

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

PCM Encore's TAK Position: Q2 2026 in Review

PCM Encore reduced its Takeda Pharmaceutical (TAK) stake by 0.82% in Q2 2026, selling an estimated $10.4K and leaving 76,278 shares worth $1.22M. The position accounts for 0.21% of the portfolio, ranked #87.

PCM Encore first reported a position in TAK in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.42M in Q1 2026. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • PCM Encore held 76,278 shares of Takeda Pharmaceutical worth $1.22M as of Q2 2026.
  • PCM Encore sold 627 Takeda Pharmaceutical shares in Q2 2026, an estimated $10.4K.
  • Takeda Pharmaceutical made up 0.21% of PCM Encore's portfolio in Q2 2026, its #87 holding.
  • PCM Encore first reported a position in Takeda Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • PCM Encore's Takeda Pharmaceutical position peaked at $1.42M in Q1 2026.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on PCM Encore's 13F filing for Q2 2026, filed 11 Aug 2026.